External comparator (EC) studies can strengthen insights from pre‑pivotal single‑arm trials by providing context to assess compound performance and guide smarter prioritization and investment decisions. By using real‑world data, EC approaches can complement traditional early-stage trials and can help accelerate development.

Webinar attendees will:

• Learn how external comparators based on real-world data can help contextualize early trial results to support decision-making
• Learn how emerging biopharma companies can use EC evidence to strengthen their value proposition
• Explore how mid-size and large pharmaceutical companies can apply EC insights to optimize late-stage asset planning
• Recognize how EC approaches can help align development decisions with patient expectations for faster information and access to novel therapies